Pfiz­er gives in­ter­im up­date on PARP in­hibitor com­bo treat­ment, earns pri­or­i­ty re­view at FDA

The com­bi­na­tion of prostate can­cer drug Xtan­di and Talzen­na, a PARP in­hibitor, re­duced the risk of death or dis­ease pro­gres­sion in metasta­t­ic prostate can­cer pa­tients, Pfiz­er said Thurs­day morn­ing.

In an in­ter­im Phase III analy­sis, Xtan­di and Talzen­na re­duced risk by 37% com­pared to Xtan­di and place­bo in metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) pa­tients, Pfiz­er said, with a p-val­ue of p<0.001. Pfiz­er pre­vi­ous­ly said the tri­al met its pri­ma­ry end­point in Oc­to­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER